I. SCIENTIFIC PAPERS

1. Jacobs WP, Case DB. Auxin transport, gibberellin, and apical dominance. Science 148:1729-1731, 1965.

2. Scott TK, Case DB, Jacobs WP. Auxin-giberellin interaction in apical dominance. Plant Physiology 42:1329-1333, 1967.

3. Case DB, Goforth JM, Silva J Jr. A case of Clostridium perfringens endocarditis. The Johns Hopkins Medical Journal 130:54.56, 1972.

4. Dell RB, Sciacca R, Lieberman K, Case DB, Cannon PJ. A weighted least squares technique for analysis of kinetic data and its application to the study of renal Xenon-133 washout in dogs and man. Circulation Research 32: 71-84, 1973.

5. Case DB, Gunther SJ, Cannon PJ. Ethacrynate-induced depression of respiration in transport systems and kidney mitochondria. American Journal of Physiology 224:769-780, 1973.

6. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SP, LeRoy EC. The relationship of hypertension and renal failure in scleroderma to structural and functional abnormalities of the renal cortical circulation. Medicine 53:1-46, 1974.

7. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a weak competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hpertensive patients. American Journal of Medicine 60:825-836, 1976.

8. Drayer JIM, Keim HJ, Weber MA, Case DB, Laragh JH. Unexpected pressor responses to propranalol in essential hypertension: an interaction between renin, aldosterone and sympathetic activity. American Journal of Medicine 60:897-903, 1976.

9. Keim HJ, JM Wallace, H Thurston, DB Case, JIM Drayer, JH Laragh. Impedance cardiography for determination of stroke index. Journal of Applied Physiology 41:797-799, 1976.

10. Case DB, Wallace JM, KeimHJ, Weber MA, Drayer JIM, White RP, Sealey JE, Laragh JH. Estimating renin participation in hpertension: superiority of converting enzyme inhibition over saralasin. American Journal of Medicine 61:790-796, 1976.

11. Keim HJ, Drayer JIM, Case DB, Lopez-Overjero JA, Wallace JM, Laragh JH. A role for renin in rebount hypertension and encephalopathy after infusion of saralasin acetate (Sar-1, Ala-8-angiotensin II). New England Journal of Medicine 295 (21): 1175-1177, 1976.

12. Weber MA, Case DB, Baer L, Sealey JE, Drayer JIM, Lopez-Ovejero JA, Laragh JH. Renin and aldosterone suppression in the antihypertensive action of clonidine. American Journal of Cardiology 38:825-830, 1976.

13. Case DB, Laragh JH. Screening for renovascular hypertension. Editorial. Cardiovascular Medicine 1:189-193, 1976.

14. Weber MA, Lopez-Ovejero JA, Drayer JIM, Case DB, Laragh JH. Renin reactivity as a determinant of responsiveness to antihypertensive treatment. Archives of Internal Medicine 137:284-289, 1977.

15. Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested b renin-sodium profiling and inhibition of converting enzyme. New England Journal of Medicine 296:641-646, 1977.

16. Laragh JH, Case DB, Wallace JM. Blockade of renin or angiotensin for understanding human hypertension: a comparison of propranolol, saralasin and converting enzyme blockade. Federation Proceedings 36:1781-1787, 1977.

17. Pollack AL, Case DB, Weber MA, Laragh JH. Limitation of transcendental meditation in the treatment of essential hypertension. The Lancet I:71-73, 1977.
18. Wallace JM, Case DB, Laragh JH, Sealey JE, Keim HJ, Drayer JIM. The immediate pressor response to saralasin: a measure of the degree of angiotension II vascular receptor vacancy. Transactions of the Association of American Physicians 40:300-312, 1977.

19. Case DB. Clinical use of angiotensin blocking agents. New York State Journal of Medicine 177:2100-2104, 1977.

20. Roberts AJ, AP Niarchos, VA Subramanian, RM Abel, JD Herman, JE Sealey, DB Case, RP White, GA Johnson, JH Laragh, WA Gay, Jr. Systemic hypertension associated with coronary artery bypass surgery: Predisposing factors, hemodynamic characteristics, humoral profile, and treatment. Journal of Thoracic and Cardiovascular Surgery 74:846-857, 1977.

21. Case DB, JH Laragh. Comments on the article: Angiotensin blockers: a totally new approach to hypertension. Current Prescribing 3:22, 1977.

22. Case DB, Casarella WJ, Fowler DL, Laragh JH, Cannon PJ. Intrarenal blood flow, renal vein renin, and magnification angiography in normal and low-renin essential hypertension. Kidney International 13:48-56, 1978.

23. Case DB. In Converting Enzyme, Angiotensin II and Hypertensive Disease. Combined Clinical and Basic Science Seminar. JH Laragh, Moderator. American Journal of Medicine 64:147-160, 1978.

24. Case DB. Hormonal aspects of essential hypertension. In Endocrine Disease and Anesthetic Management. Audio Digest. Anesthesiology Volume 19, Number 22, 1978.

25. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14,225, captopril)in hypertensive patients. Progress in Cardiovascular Disease 21:195-206, 1978.

26. Case DB. Clinical use of renin-angiotensin system blocking agents. Consultant 18:48-55, 1978.

27. Sealey JE, White RP, Laragh JH, Case DB, Rubin AL. Studies of plasma aldosterone in anephric people: evidence for the fundamental role of the renin system in maintaining aldosterone secretion. Journal of Clinical Endocrinology and Metabolism 47:52-60, 1978.

28. Wallace JM, Case DB, Laragh JH, Keim HJ, Drayer JIM, Sealey JE. The immediate pressor response to saralasin in man: a test of angiotensin II receptor vacancy. Circulation Research 44:38-44, 1979.

29. Niarchos AP, Roberts AJ, Case DB, Gay WA, Laragh JH. Hemodynamic characteristics of postcoronary artery bypass hypertension and effects of the converting enzyme inhibitor. American Journal of Cardiology 43:586-593, 1979.

30. Case DB, Wallace JM, Laragh JH. Comparison between saralasin and converting enzyme inhibitor in hypertensive disease. Kidney International 15: S107-S114, 1979.

31. Case DB, Kleiner MJ, Whitsell JC II, Laragh JH. The correction of hypertension produced by a solitary kidney with renal artery stenosis by autotransplantation. Angiology 30:351-355, 1979.

32. Atlas SA, Case DB, Sealey JE, Laragh JH, McKinstry DN. Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natriuresis. Hypertension 1:274-280, 1979.

33. Case DB, Laragh JH. Reactive hyperreninemia following angiotensin blockade with either saralasin or converting enzyme inhibitor: a new approach to screen for renovascular hypertension. Annals of Internal Medicine 91:153-160, 1979.

34. Case DB. Clues to secondary hypertension in the office visit. Practical Cardiology, Volume 5, Number 8:101-108, 1979.

35. Oberfield SE, Case DB, Levine LS, Rapaport R, Rauh W, New MI. Use of the oral angiotensin I converting enzyme inhibitor (Squibb 14225-Captopril) in childhood malignant hypertension. Journal of Pediatrics 95:641-644, 1979.

36. Niarchos AP, Pickering TG, Case DB, Sullivan PA, Laragh JH. Role of the renin angiotensin system in blooc pressure regulation: the cardiovascular effects of converting enzyme inhibition in normal man. Circulation Research 45:829-837, 1979.

37. Case DB, Atlas SA, Laragh JH. Reactive hyperreninemia to angiotensin blockade identified renovascular hypertension. Clinical Science 57:313S-316S, 1979.

38. Case DB, Fogel DH, Pollack AA, Laragh JH. Self-hypnosis and mild hypertension: a study of the acute and long term effects of self-hypnosis on blood pressure. International Journal of Clinical and Experimental Hypnosis 27:27-38, 1980.

39. Leslie BR, Case DB, Sullivan JF, Vaughan ED Jr. Absence of blood pres sure changes during effect of captopril in anephric humans. British Medical Journal 1:1067-1068, 1980.

40. Case DB, Atlas SA, Laragh JH, Sullivan PA, Sealey JE. First dose response and plasma renin predict the long-term effect of captopril. Journal of Cardiovascular Pharmacology 2:339-346.

41. Case DB, Atlas SA, Mouradian JA, Fishman RP, Sherman RA, Sealey JE, Laragh JH. Proteinuria during long-term captopril therapy. Journal of the American Medical Association 244:346-349, 1980.

42. Laragh JH, Case DB, Atlas SA, Sealey JE. Captopril compared with other antirenin system agents in hypertensive patients: its triphasic effects on blood pressure and its use to identify and treat the renin factor. Hypertension 2:586-593, 1980.

43. Case DB. Antirenin drugs in diagnosis and treatment: an alternative to plasma renin activity measurements. Cardiovascular Reviews & Reports 1:679-684, 1980.

44. Niarchos AP, Pickering TG, Case DB, Wallace JM, Laragh JH. Hemodynamic effects of the converting enzyme inhibitor in normal and high renin hypertension. Clinical Pharmacology and Therapeutics 28:592-601, 1980.

45. Case DB. New Therapy Update: Minoxidil. Cardiovascular Reviews & Reports 1:482-483, 1980.

46. Case DB, Whitman HH III, Laragh JH, Spiera H. Successful low dose captopril rechallenge following drug-induced leucopenia. Lancet 1:1362-1363, 1981.

47. Vaughan ED Jr, Case DB, Pickering TG, Sos TA, Sniderman KW, Sealey JE, Laragh JH. Diagnosis and management of renovascular hypertension. Cardiovascular Reviews & Reports 2:881-888, 1981.

48. Case DB, Atlas SA, Sullivan PA, Laragh JH. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril. Circulation 64:765-771, 1981.

49. Case DB. Diagnositic and therapeutic aspects of antiotensin blockade. Journal of St. Barnabas Medical Center, October:104-109, 1981.

50. Sos TA, Sniderman KW, Pickering TG, Case D, Vaughan ED. Percutaneous transluminal renal angioplasty (PTRA). Journal of St. Barnabas Medical Center, October:121-125, 1981.

51. Atlas SA, Case DB, Sealey JE, Laragh JH. Relationship between plasma renin and cortisol in hypertensive patients. Clinical Science 61:265-268, 1981.

52. Case DB, Atlas SA, Marion RM, Nicholson JP Jr, Parnassa E, Laragh JH. Clinical experience with captopril in moderate to severe hypertension. Cardiovascular Reviews & Reports 3:435-452, 1982.

53. Whitman HH III, Case DB, Laragh JH, Christian CL, Botstein G, Maricq H, LeRoy EC. Variable response to oral angiotensin-converting enzyme blockade in hypertensive scleroderma patients. Arthritis and Rheumatism 25:241-248, 1982.

54. Case DB, Atlas SA, Marion RM, Laragh JH. Long-term efficacy of captopril in renovascular and essential hypertension. American Journal of Cardiology 49:1440-1446, 1982.

55. Pickering TG, Case DB, Sullivan PA, Laragh JH. Comparison of antihypertensive and hormonal effects of captopril and propranolol at rest and during exercise. American Journal of Cardiology 49:1566-1568, 1982.

56. Sos TA, Saddenki S, Sniderman KW, Weiner M, Beinart C, Pickering TG, Case DB, Vaughan ED Jr, Laragh JH. Renal artery angioplasty: techniques and early results. Urology Radiology 3:223-231, 1982.

57. Sos TA, Vaughan ED Jr, Pickering TG, Case DB, Sniderman KW, Sealey JE, Laragh JH. Diagnosis of renovascular hypertension and evaluation of "surgical" curability. Urology Radiology 3: 199-203, 1982.

58. Case DB. New Therapy Update: Amiloride. Cardiovascular Reviews & Reports 3:11, 1982.

59. Case DB, Atlas SA, Marion RM, Nicholson JP, Parnassa E, Laragh JH. Clinical experience with captopril in moderate to severe hypertension. Cardiovascular Reviews & Reports 3:435-453, 1982.

60. Nicholson JP, DB Case. Carboxyhemoglobin levels in New York City runners. The Physician and Sports Medicine 12:134-138, 1983.

61. Atlas SA, Niarchos AP, Case DB. Inhibitors of the renin-angiotensin system. Effects on blood pressure, aldosterone excretion and renal function. American Journal of Nephrology 3:118-127,1983.

62. Sos TA, Pickering TG, Sniderman K, Saddekni S, Case DB, Silane MF, Vaughan ED Jr, Laragh JH. Percutaneious transluminal renal angioplasty in renovascular hypertension due to atheroma or fibromuscular dysplasia. New England Journal of Medicine 309:274-279, 1983.

63. Cody RJ, Laragh JH, Case DB, Atlas SA. Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension (Supplement III) 5:III36-III42, 1983.

64. Cody RJ, Laragh JH, Atlas SA, Case DB. Converting enzyme inhibition to identify and treat renin-mediated or sodium volume related forms of increased peripheral vascular resistance in hypertension and in congestive heart failure. Journal of Hypertension (Supplement I) 1:77-84, 1983.

65. Pickering TG, Sos TA, Vaughan ED, Case EB, Sealey JE, Harshfield GA, Laragh JH. Predictive value and changes in renin secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. American Journal of Medicine 76:39-404, 1984.

66. Muller FB, Sealey JE, Case DB, Atlas SA, Pickering TG, Pecker MS, Preibisz JJ, Laragh JH. The captopril test for identifying renovascular disease in hypertensive patients. American Journal of Medicine 80:633-644, 1986.

67. Case DB. Angiotensin converting enzyme inhibitors: are they all alike? Journal of Clinical Hypertension 3:243-256, 1987.

68. Kloner RA, Sowers JR, Dibona GF, Gaffney M, Wein M for the ACCT Study Group. Effect of amlodipine on left ventricular mass n the amlodipine cardiovascular community trial. Journal of Cardiovascular Pharmacology 26:471-476, 1995.

69. Devereux RB, Case DB, Alderman MH, Pickering TG, Chien S, Laragh JH. Possible role of increased blood viscosity in the hemodynamics of systemic hypertension. American Journal of Cardiology 85:1265-1268, 2000.


II. BOOKS, BOOK CHAPTERS AND REVIEWS

1. Capell PT, Case DB. Ambulatory Care Manual for Nurse Practitioners. Philadelphia, PA: J.B. Lippincott Company; 1976.

2. Case DB. Natural history of hypertension. In Hypertension. The Nurses Role in Ambulatory Care. M.H. Alderman, Editor; New York, NY:Springer Publishing Company, Chapter 10:99-109,
1977.

3. Laragh JH, Case DB. The renin system for understanding and managing renovascular hypertension. In Surgery of the Aorta and Its Branches. JJ Bergen, JST Yao, Editors; New York, NY; Grune and Stratton, pages 339-354, 1979.

4. Case DB. A rational base for therapeutic choice in hypertension. In Controversies in Nephrology. GE Schreiner, JF Winchester, Editors; pages 298-310, 1980.

5. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a weak competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. In Topics in Hypertension. JH Laragh, Editor; Yorke Medical Publishers, New York, NY; Volume 2, Chapter 32: 531-551, 1980.

6. Case DB, Wallace JM, Keim HJ, Weber MA, Drayer JIM, White RP, Sealey JE, Laragh JH. Estimating the renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. In Topics in Hypertension. JH Laragh, Editor; Yorke Medical Publishers, New York, NY; Volume 2, Chapter 35:577-588, 1980.

7. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14225, captopril) in hypertensive patients. In Topics in Hypertension. JH Laragh, Editor; Yorke Medical Publishers, New York, NY; Volume 2, Chapter 36:589-606, 1980.

8. Case DB, Sonnenblick EH, Laragh JH, Editors. Captopril and Hypertension. New York, NY; Plenum Publishing Company, 1980.

9. Case DB, Keim HJ, Wallace JM, Laragh JH. Experiences with blockade of the renin system in human hypertension using converting enzyme inhibitor SQ20881 and saralasin. In Captopril and Hypertension. Case DB, Sonnenblick EH, Laragh JH, Editors; Plenum Publishing Company, New York, NY; Chapter 13:185-199, 1980.

10. Case DB, Atlas SA, Laragh JH, Sealey JE, Sullivan PA, McKinstry DN. Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting enzyme inhibitor (SQ 14225, captopril) in hypertensive patients. In Captopril and Hypertension. Case DB, Sonnenblick EH, Laragh JH, Editors; Plenum Publishing Company, New York, NY; Chapter 15:211-230, 1980.

11. Vaughan ED Jr, Sos TA, Sniderman KW, Pickering TG, Case DB, Sealey JE, Laragh JH. Renal venous renin secretory patterns before and after percutaneious transluminal angioplasty: verification of the analytic criteria. In Frontiers in Hypertension Research. Laragh JH, Buhler FR, Seldin DW, Editors. Springer-Verlag, New York, NY; Session 6:173-176, 1981.

12. Atlas SA, Case DB, Sullivan PA, Sealey JE, Laragh JH. Immediate and delayed effects of angiotensin converting enzyme inhibition with captopril. In Frontiers in Hypertension Research. Laragh JH, Buhler FR, Seldin DW, Editors. Springer-Verlag, New York, NY; Session16:522-526, 1981.

13. Case DB, Atlas SA, Laragh JH. Physiologic effects and diagnostic relevance of acute converting enzyme blockade. In Frontiers in Hypertension Research. Laragh JH, Buhler FR, Seldin DW, Editors. Springer-Verlag, New York, NY; Session 17:451-550, 1981.

14. Laragh JH, Sealey JE, Vaughan ED Jr, Pickering TG, Case DB, Sos TA, Sniderman KW. Renal venous renin secretory patterns before and after percutaneious transluminal angioplasty: Verification of mathematical diagnostic criteria. In: Proceedings of the Eighth International Congress of Nephrology. Advances in Basic and Clinical Nephrology. Zurukzoglu M, Papadimitriou M, Sion M, Zamboulis, Editors. S. Karger, Basel; 457-463, 1981.

15. Vaughan ED Jr, Case DB, Pickering TG, Sos TA, Sealey JE, Laragh JH. Diagnosis and management of renovascular hypertension. In Urologic Clinic of the Medical Faculty. Belgrade; 37-48, 1981.

16. Atlas SA, Case DB. Renin in essential hypertension. In Clinics in Endocrinology and Metabolism, Endocrine Hypertension. Biglieri EG, Schambelan M, Editors. Volume 10:537-575, 1981.

17. Sos TA, Vaughan ED Jr, Pickering TG, Case DB, Sniderman KW, Sealey JE, Laragh JH. Diagnosis of renovascular hypertension and evaluation of "surgical" curability. In Transluminal Angioplasty. Castenade-Zuniga WR, Editor. Thieme-Stratton Inc, New York, NY; 57-61, 1983.

18. Case DB. Questions patients most often ask about hypertension. In Questions Patients Most Often Ask Their Doctors. Plese N, Editor. Bantam Books, New York, NY; 287-307, 1983.

19. Vaughan ED Jr, Case DB, Pickering TG, Sosa RE, Sos TA, Laragh JH. Clinical evaluation of renovascular hypertension and therapeutic decisions. In The Urologic Clinics of North America. WB Saunders Co., Philadelphia; Volume 11(3):393-408, 1984.

20. Sos TA, Pickering TG, Saddekni S, Srur M, Case DB, Silane MF, Vaughan ED Jr, Laragh JH. The current role of renal angioplasty in the treatment of renovascular hypertension. In The Urologic Clinics of North America. WB Saunders Co., Philadelphia; Volume 11(3):503-514, 1984.

21. Vaughan ED Jr, Case DB, Pickering TG, Sosa ER, Sos TA, Laragh JH. Renovascular Hypertension. In Current Trends in Urology. Resnick MI, Editor. Williams and Wilkins Co., Baltimore; 69-89, 1985.

22. Whitman HH III, Case DB, Leroy EC. Management of hypertensive scleroderma patients with converting enzyme inhibition. In Systemic Sclerosis (scleroderma). Current Topics in Rheumatology. Gower Medical Publishing Ltd, New York, NY; Volume 2:428-436, 1985.

23. Vaughan ED Jr, Pickering TG, Case DB, Sos TA, Laragh. Hypertension in renovascular disease. In Hypertension in Kidney Disease. Cheigh JS, Stenzel KH, Rubin AL, Editors. Martinus Nijhoff Publishers, Dordrecht, The Netherlands; Chapter 4:77-98, 1986.

24. Case DB. Patient population as a consideration for antihypertensive therapy. In Management of Hypertension: A Multifactoral Approach. Hollenberg NK, Editor. Butterworths, Stoneham, MA; Chapter 6:101-120, 1987.

25. Case DB. Hypertensive Emergencies. In Expert Guide to Critical Care. Raoof S, Editor. American College of Physicians Publishing. (IN PRESS).